v3.26.1
Collaboration and License Agreements (Tables)
6 Months Ended
Jun. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Revenue by Collaboration Partners

The following table summarizes the revenue by collaboration partner:

 

 

Three Months Ended

 

 

Six Months Ended

 

 

June 30,

 

 

June 30,

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

 

(in thousands)

 

 

(in thousands)

 

Amgen

$

 

 

$

332

 

 

$

 

 

$

9,818

 

Astellas

 

79

 

 

 

4,646

 

 

 

9,072

 

 

 

14,093

 

Bristol Myers Squibb

 

 

 

 

11,566

 

 

 

 

 

 

41,928

 

Regeneron

 

1,339

 

 

 

2,092

 

 

 

2,605

 

 

 

3,707

 

Moderna

 

 

 

 

22

 

 

 

 

 

 

29

 

Total revenue

$

1,418

 

 

$

18,658

 

 

$

11,677

 

 

$

69,575

 

Summary of Contract Liabilities

The following table presents changes in the Company’s total contract liabilities during the six months ended June 30, 2026 and 2025:

 

 

Deferred Revenue

 

 

(in thousands)

 

December 31, 2025

$

28,467

 

Additions

 

37,892

 

Revenue recognized

 

(11,669

)

June 30, 2026

$

54,690

 

 

 

 

December 31, 2024

$

94,063

 

Additions

 

2,803

 

Revenue recognized

 

(64,575

)

June 30, 2025

$

32,291